Satraplatin

WikiDoc Resources for Satraplatin
Articles
Most recent articles on Satraplatin Most cited articles on Satraplatin Review articles on Satraplatin Articles on Satraplatin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Satraplatin Images of Satraplatin Photos of Satraplatin Podcasts & MP3s on Satraplatin Videos on Satraplatin
Evidence Based Medicine
Cochrane Collaboration on Satraplatin Bandolier on Satraplatin TRIP on Satraplatin
Clinical Trials
Ongoing Trials on Satraplatin at Clinical Trials.gov Trial results on Satraplatin Clinical Trials on Satraplatin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Satraplatin NICE Guidance on Satraplatin NHS PRODIGY Guidance FDA on Satraplatin CDC on Satraplatin
Books
Books on Satraplatin
News
Satraplatin in the news Be alerted to news on Satraplatin News trends on Satraplatin
Commentary
Blogs on Satraplatin
Definitions
Definitions of Satraplatin
Patient Resources / Community
Patient resources on Satraplatin Discussion groups on Satraplatin Patient Handouts on Satraplatin Directions to Hospitals Treating Satraplatin Risk calculators and risk factors for Satraplatin
Healthcare Provider Resources
Symptoms of Satraplatin Causes & Risk Factors for Satraplatin Diagnostic studies for Satraplatin Treatment of Satraplatin
Continuing Medical Education (CME)
CME Programs on Satraplatin
International
Satraplatin en Espanol Satraplatin en Francais
Business
Satraplatin in the Marketplace Patents on Satraplatin
Experimental / Informatics
List of terms related to Satraplatin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

The drug is taken by mouth. It is made available in the United States jointly by Spectrum Pharmaceuticals and GPCbiotech under the name Spera.

The drug has also been used in the treatment of lung and ovarian cancers. The mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.